Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Ann, Wouters"'
Autor:
Xiaoxing, Wang, Martin E, Dowty, Ann, Wouters, Svitlana, Tatulych, Carol A, Connell, Vu H, Le, Sakambari, Tripathy, Melissa T, O'Gorman, Jennifer A, Winton, Natalie, Yin, Hernan, Valdez, Bimal K, Malhotra
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 47:419-429
Abrocitinib is a Janus kinase 1-selective inhibitor for the treatment of moderate-to-severe atopic dermatitis. Abrocitinib is eliminated primarily by metabolism involving cytochrome P450 (CYP) enzymes. Abrocitinib pharmacologic activity is attributab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d9f03f3e879e1fde1420371ca744bcb
https://doi.org/10.1007/s13318-021-00745-6
https://doi.org/10.1007/s13318-021-00745-6
Autor:
Charles Adhav, Ann Wouters, Amit V. Thorat, Arvind Chopra, Sarath Chandra Mouli Veeravalli, Vineeta Shobha, Kenneth Kwok, Shrikant Wagh, Wei Yu, Srikantiah Chandrashekara, Uppuluri R. Rao, Jugal Kishore Kadel, Paul V. Santos Estrella, Sapan Pandya, Reena Sharma
Publikováno v:
International Journal of Rheumatic Diseases
Objectives Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We characterized tofacitinib efficacy/safety in Indian vs rest of the world (ROW; excluding India) RA patients. Methods Efficacy data were pooled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af5f031f35645aae6fe2172695e4cee6
https://doi.org/10.1111/1756-185x.13853
https://doi.org/10.1111/1756-185x.13853
Autor:
Kaavya A Mohanasundaram, Naomi L Haworth, Mani P Grover, Tamsyn M Crowley, Andrzej eGoscinski, Merridee Ann Wouters
Publikováno v:
Frontiers in Pharmacology, Vol 6 (2015)
Cysteine is susceptible to a variety of modifications by reactive oxygen and nitrogen oxide species, including glutathionylation; and when two cysteines are involved, disulfide formation. Glutathione-cysteine adducts may be removed from proteins by g
Externí odkaz:
https://doaj.org/article/7942c5be93f74c52aee7f26379980db7
Autor:
Connie Chen, Lisy Wang, Ernest Choy, Koshika Soma, Pinaki Biswas, Ann Wouters, Hernan Valdez, William F. C. Rigby, Elie Needle, Kevin L. Winthrop
Publikováno v:
Annals of the Rheumatic Diseases
Herpes zoster (HZ) incidence is higher in patients with rheumatoid arthritis (RA) compared with the general population,1 and it may be further increased with disease-modifying antirheumatic drugs (DMARDs).2 Tofacitinib is an oral Janus kinase inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::accc0d2bc0536a29b918d019fb679e5c
http://europepmc.org/articles/PMC7213307
http://europepmc.org/articles/PMC7213307
Autor:
I. Tirosh, V. Chasnyk, C. Abud-Mendoza, Y. Vyzhga, Sampath Prahalad, O. Synoverska, Tracy V. Ting, I. Lazariciu, Ricardo Maisse Suehiro, A. Spindler, Ming-Ann Hsu, Hermine I. Brunner, D. Kingsbury, E. Zholobova, Keith S. Kanik, K. Marzan, Y. Butbul Aviel, B. Sözeri, N Ruperto, Yosef Uziel, L. Imundo, Richard Zhang, M. Lerman, K. Nanda, H. Schmeling, Alberto Martini, Diego O Viola, S. Vora, Vladimir Keltsev, Ann Wouters, H. Tory, C. Chang, H. Posner, Daniel J. Lovell, R Jerath
Publikováno v:
Annals of the Rheumatic Diseases. 79:180.2-181
Background:Tofacitinib is an oral JAK inhibitor that is being investigated for JIA.Objectives:To assess tofacitinib efficacy and safety in JIA patients (pts).Methods:This was a Phase 3, randomised, double-blind (DB), placebo (PBO)-controlled withdraw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1507840efd128aced3a94a8228fa394f
https://doi.org/10.1136/annrheumdis-2020-eular.396
https://doi.org/10.1136/annrheumdis-2020-eular.396
Autor:
Sergio Schwartzman, Haiyun Fan, A. Matsumoto, S. Shah, Dana E. Orange, Ann Wouters, Edward C. Keystone, R. van Vollenhoven, P. Dahl, Ryan DeMasi
Publikováno v:
Saturday, 16 JUNE 2018.
Background C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) levels are serum markers of inflammation in rheumatoid arthritis (RA). Tofacitinib is an oral JAK inhibitor for the treatment of RA. Objectives To investigate the impact of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18742fdbce323b4db0646181f5d1980c
https://doi.org/10.1136/annrheumdis-2018-eular.2676
https://doi.org/10.1136/annrheumdis-2018-eular.2676
Autor:
Ann Wouters, Michael I. Jesson, Kent J. Weinhold, Janet Staats, Todd V. Brennan, Christopher F. Mojcik, Anasuya Hazra, Jack F. Bukowski, Mark Collinge, Robert J. Noveck, Shuping Lan, Linda Stempora, Liwen Lin, James D. Clark, John B. Cheng, Constance Hammond, Pinaki Biswas, Jennifer Hodge
This study evaluated the short-term effects of tofacitinib treatment on peripheral blood leukocyte phenotype and function, and the reversibility of any such effects following treatment withdrawal in healthy volunteers. Cytomegalovirus (CMV)-seroposit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::346c09d5ac9d6ff2be4020eaa1c07d20
https://europepmc.org/articles/PMC6036921/
https://europepmc.org/articles/PMC6036921/
Autor:
Lisy Wang, Kevin L. Winthrop, W. Rigby, Pinaki Biswas, Jennifer Hodge, Irina Lazariciu, E.H. Choy, Koshika Soma, Christopher F. Mojcik, Chudy I. Nduaka, Ann Wouters
Publikováno v:
Oral Presentations.
Background Rheumatoid arthritis (RA) patients (pts) are at increased risk of herpes zoster (HZ). The most recent ACR guidelines of 2015 recommend vaccination in pts aged ≥50 years prior to starting biologic DMARDs or tofacitinib,1 an oral Janus kin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdeccabed1de143a3042684fa9511495
https://doi.org/10.1136/annrheumdis-2017-eular.2437
https://doi.org/10.1136/annrheumdis-2017-eular.2437
Publikováno v:
VLAAMS DIERGENEESKUNDIG TIJDSCHRIFT
Computertomografie is de laatste jaren meer en meer beschikbaar in de diergeneeskunde. Een belangrijke toepassing is de detectie van longnodulen bij kankerpatiënten. Het vroegtijdig opsporen is essentieel voor het bepalen van de therapie en de progn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00a44835ed815152af19ffc1caffb522
https://doi.org/10.21825/vdt.v82i2.16716
https://doi.org/10.21825/vdt.v82i2.16716
Autor:
Thomas R. Jones, Michael D. Nissen, James Baber, Qin Jiang, John L. Perez, Helen Marshall, Peter Richmond, Shannon L. Harris, Annaliesa S. Anderson, Ann Wouters, Kathrin U. Jansen
Publikováno v:
Vaccine. 31:1569-1575
Background Neisseria meningitidis serogroup B (MnB) is a leading cause of bacterial meningitis and septicemia in adolescents and young adults. No currently licensed and available vaccine has been shown to provide broad protection against endemic MnB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0516c10a515df1ec3930cbe03b3c458
https://doi.org/10.1016/j.vaccine.2013.01.021
https://doi.org/10.1016/j.vaccine.2013.01.021